Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
SAXENDAKey Asset in Novo Nordisk Obesity Market Novo Nordisk weight loss drug, SAXENDA (liraglutide), is a GLP-1 receptor agonist designed to support long-term weight loss when combined with a reduced-calorie diet and increased physical activity
References Sugawara M et al
Treatment of Type 2 Diabetes Dietary and Lifestyle Considerations Blood sugar control (as assessed by the HbA1C test) is the primary goal of diabetes treatment
Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus
The most frequently reported symptoms included: Nausea (the most common, with rates varying by dose readers should refer to the published trial data and supplementary tables for dose-specific figures) Vomiting Diarrhoea Constipation Upper abdominal pain or discomfort Decreased appetite These effects are largely attributable to the drug's action on GLP-1 receptors in the gastrointestinal tract, which slow gastric motility and alter gut hormone signalling
